NDA 022156 · Chiesi
Cleviprex
Clevidipine · Intravenous · Dihydropyridine Calcium Channel Blocker
NovelLast checked: Nov 20, 2026Latest source record: Apr 16, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2008
Aug 1, 2008
Approved uses
1
Original approval plus efficacy supplements
Registered trials
30
15 Phase 3, 1 recruiting
FAERS reports
367
226 serious, 23 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 6, 2025.
Cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. Cleviprex is a dihydropyridine calcium channel blocker indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. (1)
Mechanism: Clevidipine is a dihydropyridine L-type calcium channel blocker. L-type calcium channels mediate the influx of calcium during depolarization in arterial smooth muscle. Experiments in anesthetized rats and dogs show that clevidipine reduces mean arterial blood pressure by decreasing systemic vascular resistance. Clevidipine does not reduce cardiac filling pressure (pre-load), confirming lack of effects on the venous capacitance vessels.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 1, 2008 Original approval · Type 1 - New Molecular Entity NovelSummary ReviewReviewLetter
3 products under this application
- CLEVIPREX · CLEVIDIPINE 50MG/100ML (0.5MG/ML) · EMULSION, INTRAVENOUS · Prescription
- CLEVIPREX · CLEVIDIPINE 125MG/250ML (0.5MG/ML) · EMULSION, INTRAVENOUS · Discontinued
- CLEVIPREX · CLEVIDIPINE 25MG/50ML (0.5MG/ML) · EMULSION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Clevidipine" as an intervention, any sponsor and status, largest first.
- Clevidipine in the Postoperative Treatment of Hypertension (ECLIPSE-NIC)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093925 · 739 participants · Start May 2004 · Primary completion Jul 2006
Drug: clevidipine; nicardipine · For: Hypertension
Sites: Mobile, Alabama; Wichita, Kansas; New Orleans, Louisiana · 9 sites in all
- Clevidipine in the Perioperative Treatment of Hypertension (ECLISPE-SNP)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093912 · 739 participants · Start Jun 2004 · Primary completion Oct 2006
Drug: clevidipine; sodium nitroprusside · For: Hypertension
Sites: Birmingham, Alabama; Montgomery, Alabama; Burbank, California · 29 sites in all
- Clevidipine in the Perioperative Treatment of Hypertension (ECLIPSE-NTG)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093886 · 629 participants · Start Apr 2004 · Primary completion Mar 2005
Drug: clevidipine; nitroglycerin · For: Hypertension
Sites: Birmingham, Alabama; Montgomery, Alabama; Tucson, Arizona · 28 sites in all
- A Study of Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergencyPivotal-lookingStatus unknown
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT05783557 · 398 participants (planned) · Start May 1, 2023 · Primary completion Dec 1, 2024
Drug: Clevidipine Butyrate Injectable Emulsion; Cleviprex® · For: Hypertensive Emergency
- a Study Evaluating the Safety and Efficacy of Clevidipine for Patients Who With Hypertensive Emergency and Sub-emergencyPivotal-lookingStatus unknown
Qilu Pharmaceutical (Hainan) Co., Ltd.Industry
NCT05922436 · 378 participants (planned) · Start Jul 15, 2023 · Primary completion May 24, 2024
Drug: QLG2071; Cleviprex® · For: Hypertensive Emergency
- Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive EmergenciesPivotal-lookingStatus unknown
Nanjing Yoko Biomedical Co., Ltd.Industry
NCT04670809 · 262 participants (planned) · Start Jul 27, 2020 · Primary completion Aug 2021
Drug: Clevidipine Butyrate Injection; Ncardipine Hydrochloride Injection · For: Hypertensive Emergency
Sites: Beijing, China · 2 sites in all
- Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00093262 · 206 participants · Start Dec 2003 · Primary completion Oct 2004
Drug: clevidipine; placebo · For: Hypertension
Sites: Mobile, Alabama; Los Angeles, California; Pasadena, California · 15 sites in all
- Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)Pivotal-lookingCompleted
The Medicines CompanyIndustry
NCT00369837 · 131 participants · Start Sep 2006 · Primary completion Jan 2007
Drug: clevidipine · For: Hypertension
Sites: Montgomery, Alabama; Los Angeles, California; Washington D.C., District of Columbia · 14 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective36
- hypotension30
- hypoxia27
- ventilation perfusion mismatch25
- oxygen saturation decreased18
- tachycardia17
- atrial fibrillation15
- bradycardia13
- extravasation13
- blood pressure inadequately controlled11
- off label use11
- infusion site extravasation10
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 1 |
| 2009 | 77 |
| 2010 | 18 |
| 2011 | 12 |
| 2012 | 5 |
| 2013 | 3 |
| 2014 | 17 |
| 2015 | 12 |
| 2016 | 25 |
| 2017 | 7 |
| 2018 | 21 |
| 2019 | 25 |
| 2020 | 29 |
| 2021 | 16 |
| 2022 | 24 |
| 2023 | 27 |
| 2024 | 20 |
| 2025 | 17 |
| 2026 | 11 |
Recalls
1 FDA enforcement reports for this application.
Jul 6, 2026 · Class II · Ongoing
Lack of Assurance of Sterility
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of clevidipine emulsion injection compared with nicardipine in patients with hypertensive emergencies: a randomized, single-blind, positive-parallel-controlled, phase III clinical trial.
Lv Q, Chen C, Lin L, et al. · J Hypertens 2026 · Clinical Trial, Phase III, Randomized Controlled Trial
- Perioperative Use of Clevidipine: A Systematic Review and Meta-Analysis.
Espinosa A, Ripollés-Melchor J, Casans-Francés R, et al. · PLoS One 2016 · Meta-Analysis, Systematic Review
- The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients.
Aronson S, Dyke CM, Stierer KA, et al. · Anesth Analg 2008 · Comparative Study, Randomized Controlled Trial
- Comparison between clevidipine and nicardipine in cerebrovascular diseases: A systematic review and meta-analysis.
Seifi A, Azari Jafari A, Mirmoeeni S, et al. · Clin Neurol Neurosurg 2023 · Meta-Analysis, Systematic Review
- Efficacy and Safety of a Generic Clevidipine in Hypertensive Urgencies and Non-Fulminant Hypertensive Emergencies: A Phase III, Multicenter, Randomized, Double-Blind, Positive Drug Parallel-Controlled Study.
Han X, Ma W, Wang B, et al. · J Clin Hypertens (Greenwich) 2025 · Randomized Controlled Trial, Multicenter Study
- The safety and efficacy of clevidipine for blood pressure management in neurocritical patients: a systematic review and meta-analysis.
Widiastuti M, Bisri DY, Rachman IA · Sci Rep 2024 · Meta-Analysis, Systematic Review
Sponsor: Chiesi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.